MedTrace Logo

Re-treatment of Participants With Paget's Disease Using Zoledronic Acid

NCT00740129 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2021-05-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to demonstrate that participants with Paget's disease of the bone who had responded to zoledronic acid treatment as participants in the core registration studies CZOL446K2304 and CZOL446K2305 and later experienced a relapse can be successfully treated with a 5 milligram (mg) infusion of zoledronic acid.

Conditions

  • Paget's Disease of the Bone

Interventions

DRUG

Zoledronic Acid

Zoledronic acid 5 mg intravenous infusion once

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-21
Primary Completion
2011-03-14
Completion
2011-03-14
FDA Drug
Yes

Countries

  • Belgium
  • Canada
  • New Zealand
  • South Africa
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00740129 on ClinicalTrials.gov